The use of G-protein coupled receptor models in lead optimization.
暂无分享,去创建一个
[1] Sadashiva S Karnik,et al. Multiple Signaling States of G-Protein-Coupled Receptors , 2005, Pharmacological Reviews.
[2] David A Kendall,et al. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. , 2005, Bioorganic & medicinal chemistry letters.
[3] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[4] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[5] A. Tebben,et al. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. , 2009, Methods in enzymology.
[6] Kenneth Lundstrom,et al. Latest development in drug discovery on G protein-coupled receptors. , 2006, Current protein & peptide science.
[7] A. Eckhart,et al. Regulation of GPCR signaling in hypertension. , 2010, Biochimica et Biophysica Acta.
[8] E. Bradley,et al. Performance of 3D-database molecular docking studies into homology models. , 2004, Journal of medicinal chemistry.
[9] Ania de la Nuez Veulens,et al. G Protein-coupled receptors as targets for drug design , 2009 .
[10] S. Hill,et al. G‐protein‐coupled receptors: past, present and future , 2006, British journal of pharmacology.
[11] Maya Topf,et al. PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.
[12] Junmei Wang,et al. GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..
[13] Herbert Köppen. Virtual screening - what does it give us? , 2009, Current opinion in drug discovery & development.
[14] Bernard Maigret,et al. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? , 2003, Trends in pharmacological sciences.
[15] R. Singh,et al. Rational design of CCR2 antagonists: a survey of computational studies , 2010, Expert opinion on drug discovery.
[16] R. Flaumenhaft,et al. Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism. , 2010, Current vascular pharmacology.
[17] J. Wess,et al. Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.
[18] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[19] Tsutomu Kouyama,et al. Crystal structure of squid rhodopsin , 2008, Nature.
[20] W. Koch,et al. Future G protein-coupled receptor targets for treatment of heart failure , 2009, Current treatment options in cardiovascular medicine.
[21] K. Mohr,et al. Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.
[22] Claudio N. Cavasotto,et al. Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.
[23] Nagarajan Vaidehi,et al. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. , 2010, Journal of the American Chemical Society.
[24] K. Jacobson,et al. P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. , 2007, Journal of medicinal chemistry.
[25] Stefano Costanzi,et al. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.
[26] H. Stark,et al. Refined Docking as a Valuable Tool for Lead Optimization: Application to Histamine H3 Receptor Antagonists , 2008, Archiv der Pharmazie.
[27] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[28] H. Almond,et al. Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment. , 2007, Bioorganic & medicinal chemistry letters.
[29] Christopher J Langmead,et al. Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors , 2009, Molecular Pharmacology.
[30] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[31] Bo Li,et al. Rapid identification of functionally critical amino acids in a G protein–coupled receptor , 2007, Nature Methods.
[32] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.
[33] Stefano Costanzi,et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.
[34] I. Forbes,et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. , 2003, Journal of medicinal chemistry.
[35] Y. Okayama,et al. Targeting human mast cells expressing g-protein-coupled receptors in allergic diseases. , 2008, Allergology international : official journal of the Japanese Society of Allergology.
[36] J. Wess,et al. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.
[37] D. Selley,et al. Cannabinoid CB1 receptor‐interacting proteins: novel targets for central nervous system drug discovery? , 2010, British journal of pharmacology.
[38] Christophe Chipot,et al. Milestones in the Activation of a G Protein-Coupled Receptor. Insights from Molecular-Dynamics Simulations into the Human Cholecystokinin Receptor-1. , 2008, Journal of chemical theory and computation.
[39] Christopher G. Tate,et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.
[40] Tracy M Handel,et al. Chemokine: receptor structure, interactions, and antagonism. , 2007, Annual review of immunology.
[41] M. Ishii,et al. Muscarinic acetylcholine receptors. , 2006, Current pharmaceutical design.
[42] A. Rayan. New vistas in GPCR 3D structure prediction , 2010, Journal of molecular modeling.
[43] Nagarajan Vaidehi,et al. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. , 2010, Drug discovery today.
[44] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[45] A. Sali,et al. Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.
[46] J. Crook,et al. G-protein Coupled Receptors in Stem Cell Self-Renewal and Differentiation , 2010, Stem Cell Reviews and Reports.
[47] H. Senderowitz,et al. G protein coupled receptors -in silico drug discovery and design. , 2010, Current topics in medicinal chemistry.
[48] D. Selley,et al. 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies. , 2009, Bioorganic & medicinal chemistry letters.
[49] C. Langmead,et al. Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands , 2007, Molecular Pharmacology.
[50] Wolfgang Guba,et al. Focused library design in GPCR projects on the example of 5‐HT2c agonists: Comparison of structure‐based virtual screening with ligand‐based search methods , 2005, Proteins.
[51] J. Saldanha,et al. Structure and activation of muscarinic acetylcholine receptors. , 2001, Biochemical Society transactions.
[52] Y. Wong,et al. G protein signaling controls the differentiation of multiple cell lineages , 2009, BioFactors.
[53] N. Vaidehi,et al. Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5 , 2009, Molecular Pharmacology.
[54] P. Carloni,et al. G protein inactive and active forms investigated by simulation methods , 2009, Proteins.
[55] Stefano Costanzi,et al. Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands , 2009, J. Comput. Aided Mol. Des..
[56] Davide Provasi,et al. Putative active states of a prototypic g-protein-coupled receptor from biased molecular dynamics. , 2010, Biophysical journal.
[57] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[58] Edgar Jacoby,et al. The 7 TM G‐Protein‐Coupled Receptor Target Family , 2006, ChemMedChem.
[59] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[60] Raphael Nudelman,et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.
[61] J. Wess,et al. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor. , 2002, Biochemistry.
[62] Michael Wiese,et al. Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243 , 2006, J. Comput. Aided Mol. Des..
[63] E. Altmann,et al. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. , 2010, Journal of medicinal chemistry.
[64] Andreas Hildebrandt,et al. Revisiting automated G-protein coupled receptor modeling: the benefit of additional template structures for a neurokinin-1 receptor model. , 2009, Journal of medicinal chemistry.
[65] Nagarajan Vaidehi,et al. First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin. , 2004, Biophysical journal.
[66] Udo Höweler,et al. Simulations of a G protein‐coupled receptor homology model predict dynamic features and a ligand binding site , 2008, FEBS letters.
[67] Arne Elofsson,et al. Using multiple templates to improve quality of homology models in automated homology modeling , 2008, Protein science : a publication of the Protein Society.
[68] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[69] Peter L. Freddolino,et al. Prediction of structure and function of G protein-coupled receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. Wess,et al. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. , 1992, The Journal of biological chemistry.
[71] T. Tuccinardi,et al. An overview of recent developments in GPCR modelling: methods and validation , 2006, Expert opinion on drug discovery.
[72] Nagarajan Vaidehi,et al. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. , 2008, Journal of molecular biology.
[73] D. Sheehan,et al. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling. , 1997, Molecular pharmacology.
[74] Jürgen Bajorath,et al. Chemoinformatics and Computational Chemical Biology , 2011, Methods in Molecular Biology.
[75] Xi-Ping Huang,et al. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors , 1999, British journal of pharmacology.
[76] Andreas Evers,et al. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.
[77] A. Krejci,et al. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. , 2001, Molecular pharmacology.
[78] J W Saldanha,et al. Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch* , 2001, The Journal of Biological Chemistry.
[79] Ning Ren,et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. , 2008, Bioorganic & medicinal chemistry letters.
[80] Ravinder Abrol,et al. Predictions of CCR1 Chemokine Receptor Structure and BX 471 Antagonist Binding Followed by Experimental Validation* , 2006, Journal of Biological Chemistry.
[81] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[82] R. Wolf,et al. Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.
[83] E. Hulme,et al. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.
[84] Ian T. Crosby,et al. Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..
[85] Gerhard Hummer,et al. Atomistic insights into rhodopsin activation from a dynamic model. , 2008, Journal of the American Chemical Society.
[86] Andrej ⩽ali,et al. Comparative protein modeling by satisfaction of spatial restraints , 1995 .
[87] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[88] Fu-Yue Zeng,et al. Random Mutagenesis of the M3 Muscarinic Acetylcholine Receptor Expressed in Yeast , 2003, Journal of Biological Chemistry.
[89] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[90] C. Fraser. G Protein–Coupled Receptor Connectivity to NF-κB in Inflammation and Cancer , 2008, International reviews of immunology.
[91] Marta Filizola,et al. Advances in the development and application of computational methodologies for structural modeling of G-protein-coupled receptors , 2008, Expert opinion on drug discovery.
[92] J. Wess,et al. Conformational Changes That Occur during M3Muscarinic Acetylcholine Receptor Activation Probed by the Use of an in Situ Disulfide Cross-linking Strategy* , 2002, The Journal of Biological Chemistry.
[93] Patricia Andrade-Gordon,et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. , 2002, Angewandte Chemie.
[94] Juan Jesús Pérez,et al. BUNDLE: A program for building the transmembrane domains of G-protein-coupled receptors , 1998, J. Comput. Aided Mol. Des..
[95] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[96] O. Civelli,et al. Orphan GPCR research , 2008, British journal of pharmacology.
[97] M. Nowak,et al. Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry. , 2006, Journal of medicinal chemistry.
[98] K. Jacobson. Introduction to adenosine receptors as therapeutic targets. , 2009, Handbook of experimental pharmacology.
[99] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[100] A. Mantovani,et al. Chemokines as pharmacological targets. , 2008, Mini reviews in medicinal chemistry.
[101] T. Schwartz,et al. Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.
[102] E. Kellenberger,et al. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.
[103] Suzie Chen,et al. G‐protein‐coupled receptors and melanoma , 2008, Pigment cell & melanoma research.
[104] O. Civelli,et al. Orphan G protein‐coupled receptors: targets for new therapeutic interventions , 2004, Annals of medicine.
[105] C. Chipot,et al. Large-scale molecular dynamics of a G protein-coupled receptor, the human 5-HT4 serotonin receptor, in a lipid bilayer , 2007 .
[106] B B Fredholm,et al. G‐protein‐coupled receptors: an update , 2007, Acta physiologica.
[107] Marta Filizola,et al. Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.
[108] D. Langley,et al. Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach , 2008, Proteins.
[109] Prashant V Desai,et al. Ligand‐supported homology modeling of the human angiotensin II type 1 (AT1) receptor: Insights into the molecular determinants of telmisartan binding , 2006, Proteins.
[110] A. Sali,et al. Protein Structure Prediction and Structural Genomics , 2001, Science.
[111] T. Williams,et al. Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation* , 2007, Journal of Biological Chemistry.
[112] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[113] Xuehua Xu,et al. Chemotaxis, chemokine receptors and human disease. , 2008, Cytokine.
[114] X. Huang,et al. Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[115] Alexander Pautsch,et al. The Implication of the First Agonist Bound Activated GPCR X-ray Structure on GPCR in Silico Modeling. , 2011, ACS medicinal chemistry letters.
[116] Arthur M. Lesk,et al. Introduction to bioinformatics , 2002 .
[117] Patrick Scheerer,et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.
[118] Audrey Claing,et al. Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. , 2005, Current opinion in drug discovery & development.
[119] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.